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SUPPORTING INFORMATION 
Synthesis of the probes 
The synthesis of 2-fluoro-glucopyranose probes commences with the synthesis of 2-fluoro-
glucopyranoside 11. To obtain this intermediate we applied the direct electrophilic fluorination of 
3,4,6-tri-O-acetyl-D-glucal method using Selectfluor, as developed by Dax et al.[1] The major drawback 
of this facile method is that an epimeric mixture is produced of manno/gluco-pyranosides in a almost 
equal ratio. However, upon acetylation of the anomeric hydroxyl, the gluco epimer can be isolated. 
 
Scheme 1. Synthesis of key intermediate 18. Reagents and conditions: a) Selectfluor, NO2Me, then 
Ac2O, pyridine; b) HBr/AcOH, DCM; c) TolSH, TBAB, aq. KOH, CHCl3 (83% over 2 steps); d) 
NaOMe, MeOH (quant.); e) Ts2O, NEt3, dioxane (52%); f) NaN3, DMF, 80 °C; g) Ac2O, pyridine 
(69% over 2 steps); h) NBS, acetone/H2O (86%). 
Starting from 1,3,4,6-tetra-O-acetyl-2-deoxy-2-fluoro-α/β-D-glucopyranoside 11, the anomeric acetyl 
was brominated using HBr/AcOH in DCM, and after aqueous work-up subsequently substituted with 
an S-toluyl moiety to yield β-thio compound 13 as the sole anomer (83% over two steps). 
Deacetylation using Zemplén conditions resulted in triol 14 in quantitative yield. When compound 14 
was treated with tosyl chloride in pyridine to regioselectively introduce a tosyl functionality at C-6, a 
substantial amount of the 6-chloride was isolated together with the desired 6-O-tosylate. Since the 6-
chloride showed a similar behavior on TLC as the 6-O-tosylate, it was impossible to efficiently isolate 
desired compound 15. However, formation of the 6-chloride was suppressed when compound 14 was 
reacted with tosyl anhydride in dioxane and compound 15 was obtained in moderate yield (52%). 
Subsequent substitution of the tosyl functionality with NaN3 in DMF at 80 °C, followed by acetylation 
of C-3 and C-4 (Ac2O/pyridine) gave compound 17 in 69% over two steps. In a first attempt to 
synthesize β-fluoride compound 6, thioglucoside 17 was treated with DAST/NBS in DCM over 3 days 
to produce solely the α-fused anomeric fluoride product in 85%. A possible explanation for this high 
α-selectivity is that the activated β-thio functionality is not very prone to leave and is therefore 
substituted in an SN2-like manner to produce the α-product. The electron-withdrawing fluoride at C-2 
and the azide at C-6 are believed to lie at the base of this inreactivity. We now turned our attention to 
the hemiacetal 18, from which both the anomeric fluoride and the 2,4-dinitrophenyl glucosides could 
be synthesized. To obtain key intermediate 18, the anomeric thio functionality was hydrolyzed using 
the NIS/TFA method.[2] Surprisingly, the reaction was very slow and resulted after long reaction times 
and an excess of reagents in a mixture of the desired hemiacetal product and a diastereomeric mixture 
of β-sulfoxides. Switching of the solvent system from DCM to acetone/H2O resulted in practically no 
conversion of starting compound 17. The use of NBS as the electrophilic thio activator gave the best 
results, since TLC analysis revealed quick consumption of the starting compound (~ 10 min) to the 
sulfoxides, which were hydrolysed with additional NBS overnight to yield hemiacetal product 18 in 
86%. When hemiacetal 18 was treated with DAST at -45 °C  for 3 h, a mixture of anomeric fluorides 
was obtained with the β-fused product as the major isomer (α : β = 1 : 4). Fast deacetylation using 
stoichiometric NaOMe resulted in the formation of a substantial amount of the α-O-methyl glucoside 
by direct substitution of the anomeric fluoride functionality. On the other hand, a catalytic amount of 
NaOMe in MeOH yielded MW447 6 quantitatively. To produce 2,4-dinitrophenyl glucoside 9, 
hemiacetal 18 was treated with 2,4-dinitrofluorobenzene and DABCO in DMF. A mixture of anomers 
was produced of which the β-fused product could be isolated in 36%. Deacetylation was accomplished 
under acidic conditions (AcCl in MeOH) to yield 9 in 89%.  
Scheme 2. Synthesis of the 2-fluoro glucoside probes. Reagents and conditions: a) DAST, DCM 
(64%); b) NaOMe, MeOH (quant.); c) 2,4-dinitrofluorobenzene, DABCO, DMF (36%); d) AcCl, 
MeOH (89%); e) BODIPY-alkyne 10, sodium ascorbate, CuSO4, DMF (MW448 4: 56%, MW454 7: 
36%); f) BODIPY-alkyne 19, sodium ascorbate, CuSO4, DMF (MW461 5: 21%, MW462 8: 32%). 
Using the copper-catalyzed click reaction,[3] 6-azido-2-fluoro glucoside probes MW447 6 and MW436 
9 were conjugated with BODIPY-alkyne 10 (green emission) and BODIPY-alkyne 19 (red emission). 
In this way, the four direct probes MW448 4, MW454 5, MW461 7 and MW462 8 were obtained 
(Scheme 2). 
Determination of the binding-constants. 
The binding-constants of the probes for almond β-glucosidase and for glucocerebrosidase were 
determined using an indirect fluorescent substrate assay. By plotting the residual activity versus the 
time the apparent rate constant could be determined. The resulting progress curves can be seen in 
Figure 1 and 2 (left panels). To determine the constant for initial binding (Ki) and the rate constant (ki), 
the apparent rate constants were plotted versus the concentration (Figure 1 and 2 right panels). 
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Figure 1. Determination of the binding-constants of the probes for almond β-glucosidase. (left) 
Progress curves. [E]/[E0] is the residual activity (fluorescence at time point x divided by the 
fluorescence at time point zero). (right) Kitz-Wilson plot of the pseudo-first order rate constants (k’).  
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Figure 2. Determination of the binding-constants of the probes for GBA. (left) Progress curves. 
[E]/[E0] is the residual activity (fluorescence at time point x divided by the fluorescence at time point 
zero). (right) Kitz-Wilson plot of the pseudo-first order rate constants (k’). 
Two-step labeling: Staudinger ligation versus copper catalyzed click-reaction. 
To compare the efficiency of the two-step labeling, GBA-1 was inhibited with the probe (10 µM) and 
subsequently either subjected to either biotinylated Staudinger-Bertozzi phosphane 20 (400 µM for 4h 
in the presence of 8 M urea) or biotin-derived alkyne 21 in the presence of Cu(I) (100 µM for 16h in 
NaOAc buffer containing 1% SDS) (figure 3a).[4, 5] The labeled proteins were visualized by western 
blotting. As can bee seen in figure 3 the copper-catalyzed click ligation gave a stronger signal then the 
Staudinger-Bertozzi ligation. Exposure of the film for 10 seconds gave a good signal for the copper-
catalyzed click reaction (Figure 3b). This is not the case for protein labeled with the two-step probe 
and visualized with the Staudinger ligation. These only revealed a signal after 5 minutes of exposure 
(3c). 
 
Figure 3. Functionalisation of the azido group using either Staudinger ligation or the copper catalyzed 
click-reaction. (a) Structures of the biotinylated compounds used. (b) 10 seconds exposure of the film. 
(c) 5 minute exposure of the exact same western blot. (d) Functionalisation of the azido group with 
BODIPY-alkyne 10. 
Labeling of retaining beta-glucosidases. 
Next to labeling with the green fluorescent probes, we also labeled GBA-1 and almond β-glucosidase 
with probes containing a red fluorophore. Labeling with these probes is very similar to labeling with 
green fluorescent probes 1, 4 and 7. Cyclophellitol probe 2 and 2-deoxy-2-fluoroglucoside probe 5 
label GBA-1 in a concentration dependent fashion, whereas dinitrophenyl containing probe 8 did not 
label GBA-1 at all, a feat which was also observed for the green probes. Moreover, the red probes 
hardly label almond β-glucosidase (Figure 4).  
 
Figure 4. Labeling of beta glucosidases with red fluorescent probes 2, 5 and 8. (a) Labeling of almond 
β-glucosidase. (b) Labeling of GBA-1. 
The gels of GBA-1 that was labeled the 2-deoxy-2-fluoride probes 4 and 5 revealed only a faint signal. 
We reasoned that this was caused by incomplete inactivation of the enzyme. The progress curves of 
the kinetic experiments (Figure 1a) show that only a small portion of GBA-1 is inhibited at the time 
and concentration used. Furthermore, the progress curves demonstrate that nearly complete inhibition 
of the enzyme can be achieved by treating the enzyme for 6 hours with 100-400 µM. We therefore 
reasoned that increasing the labeling time and the concentration would lead to an enhanced signal and 
indeed this is the case as can be seen in Figure 5.  
 
Figure 5. Time dependency of labeling with 4, 5, 7 and 9. 
Having optimized the labeling conditions, we tested the requirement of active enzyme for labeling as 
described in the main text of the manuscript (Figure 6). 
 
 
Figure 6. Labeling by 3, 4 and 5 requires active enzyme. Lane 1: GBA-1 was treated with probe (3: 10 
μM, 4: 400 μM and 5: 100 μM) at 37°C for 30 min (3) or 6 h (4 and 5). Lane 2: GBA-1 was pretreated 
with CBE (2 mM) for 30 min followed by incubating with probe (similar concentrations were used as 
in the control). Lane 3: GBA-1 was incubated with the probe in the presence of AMP-DNM (2 mM). 
Lane 4: GBA-1 was heat denatured with 1% SDS prior to labeling with the probe. 
Finally, we tested the sensitivity of the probes. Decreasing amounts of enzyme were incubated with 
the probe. As shown in the manuscript the sensitivity of the two-step probes and the direct, green 
fluorescent probes are in the same range. The same counts for the red-fluorescent probes, except for 
almond β-glucosidase which is labeled far better by two-step probe 3 than the direct probe (Figure 
7A). Furthermore, we tested the sensitivity of 2-deoxy-2-fluoroglycoside probes 4 and 5 for 
recombinant purified glucocerebrosidase. These probes are as sensitive as the cyclophellitol probes 
when enzyme was subjected to concentrations > 100 μM for 6h, conditions clearly not suitable for in 
cell-labeling. 
 
Figure 7. A, B, C) Sensitivity of the red fluorescent probe versus the two-step probe in combination 
with BODIPY 19. D) Sensitivity of 2-deoxy-2-fluoroglycoside probes 4 and 5.  
Experimental section 
All reagents were of commercial grade and used as received unless stated otherwise. Diethyl ether 
(Et2O), ethyl acetate (EtOAc), light petroleum ether and toluene were obtained from Riedel-de Haën. 
Acetonitrile, dichloromethane, N,N-dimethylformamide (DMF), methanol (MeOH), pyridine, 
tetrahydrofuran (THF) were purchased from Biosolve. Dichloromethane was distilled from CaH2 and 
THF was distilled over LiAlH4 prior to use. All reactions were performed under an inert atmosphere of 
Argon unless stated otherwise. Solvents used for flash chromatography were of pro analysi quality.  
Reactions were monitored by TLC analysis using Merck aluminum sheets precoated with silica gel 60 
with detection by UV-absorption (254 nm) and by spraying with a solution of (NH4)6Mo7O24.H2O (25 
g/L) and (NH4)4Ce(SO4)4.H2O (10 g/L) in 10% sulfuric acid followed by charring at ~150°C or by 
spraying with 20% sulfuric in ethanol followed by charring at ~150°C. Column chromatography was 
performed using either Baker- or Screening Device silica gel in the indicated solvents. 1H NMR and 
13C NMR spectra were recorded on a Bruker DMX-400 (400/100 MHz) or a Bruker AV-400 (400/100 
MHz) spectrometer in the given solvent. Chemical shifts are reported as δ-values in ppm relative to 
the chloroform residual solvent peak or tetramethylsilane (TMS) as internal standard. Coupling 
constants are given in Hz. All given 13C spectra are proton decoupled. Spin multiplicities are given as 
s, d, dd, ddd, dddd, dt, t, td, q and m. High resolution mass spectra were recorded with a LTQ Orbitrap 
(Thermo Finnigan). LC/MS analysis was performed on a Jasco HPLC-system (detection 
simultaneously at 214 nm and 254 nm) equipped with an analytical Alltima C18 column (Alltech, 4.6 
mmD × 50 mmL, 3μ particle size) in combination with buffers A: H2O, B: acetonitrile and C: 1% aq. 
TFA and coupled to a Perkin Elmer Sciex API 165 mass instrument. Optical rotations were measured 
on a Propol automatic polarimeter (sodium D line, λ = 589 nm). FT-IR-spectra were recorded on a 
Paragon-PE 1000. 
1,3,4,6-Tetra-O-acetyl-2-deoxy-2-fluoro-α /β-D-glucopyranoside (11). 
The title compound was synthesized according to a procedure described 
by Priebe et al.[6] and the analytical data is in accordance to those described. TLC: Rf 0.61 (PE/EtOAc, 
1/1, v/v); IR (neat, cm-1): 1036, 1211, 1369, 1747; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): 
δ 6.28 (d, 0.78H, J = 3.9 Hz, H-1α), 5.70 (dd, 1H, J = 3.1, 8.1 Hz, H-1β), 5.40 (dt, 0.78H, J = 9.6, 
12.2 Hz, H-3α), 5.29 (dt, 1H, J = 9.3, 14.3 Hz, H-3β), 4.95 (t, 0.78H, J = 9.9 Hz, H-4α), 4.92 (t, 1H, J 
= 4.9 Hz, H-4β), 4.55 (ddd, 0.78H, J = 4.0, 9.6, 48.5 Hz, H-2α), 4.31 (dt, 1H, J = 8.6, 50.9 Hz, H-2β), 
4.17 (t, 0.78H, J = 4.7 Hz, H-6α), 4.14 (t, 1H, J = 4.7 Hz, H-6β), 3.88-4.00 (m, 2.56H, H-5α, H-6α, 
H-6β), 3.79 (ddd, 1H, J = 2.1, 4.4, 10.1 Hz, H-5β), 2.06 (s, 2.31H, CH3 Ac-α), 2.03 (s, 3H, CH3 Ac-β), 
1.94 (s, 6H, CH3 Ac-β), 1.93 (s, 4.92H, CH3 Ac-α), 1.90 (s, 2.31H, CH3 Ac-α), 1.89 (s, 3H, CH3 Ac-
β); 13C-APT NMR (CDCl3, 100 MHz, HSQC): δ 170.1, 169.7, 169.4, 169.1, 169.1, 168.4, 168.3 (C=O 
Ac), 90.8 (d, J = 24 Hz, C-1β), 87.9 (d, J = 190 Hz, C-2β), 87.9 (d, J = 22 Hz, C-1α), 85.8 (d, J = 193 
Hz, C-2α), 72.2 (d, J = 19 Hz, C-3β), 72.2 (C-5β), 70.2 (d, J = 19 Hz, C-3α), 69.1 (C-5α), 67.2 (d, J = 
7 Hz, C-4β), 67.0 (d, J = 7 Hz, C-4α), 61.0 (C-6), 20.4, 20.2, 20.1 (CH3 Ac); HRMS: [M+Na]+ calcd 
for C14H19FO9Na 373.0905, found 373.0905. 
 
Tolyl 3,4,6-tri-O-acetyl-2-deoxy-2-fluoro-1-thio-β-D-glucopyranoside 
(13). A solution of compound 11 (5.2 g, 14.8 mmol) in dry DCM (10 mL) 
was cooled to 0 °C and HBr in AcOH (33wt%, 12.8 mL, 74 mmol) was added. The resulting solution 
was stirred at 4 °C overnight, after which the mixture was poured in ice water, diluted with EtOAc and 
washed with H2O (2x) and sat. aq. NaCl. The combined aqueous layers were extracted with EtOAc 
and the resulting organic fractions were dried over Na2SO4, filtered, concentrated in vacuo and co-
evaporated with toluene (3x). The crude product 12 was then used in the next reaction step without 
further purification. (TLC: Rf 0.42 (PE/EtOAc, 2/1, v/v); IR (neat, cm-1): 729, 1038, 1209, 1367, 1744; 
1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 6.55 (d, 1H, J = 4.3 Hz, H-1), 5.63 (dt, 1H, J = 
9.4, 11.2 Hz, H-3), 5.12 (t, 1H, J = 9.9 Hz, H-4), 4.55 (ddd, 1H, J = 4.3, 9.4, 49.4 Hz, H-2), 4.29-4.37 
(m, 2H, H-5, H-6), 4.10-4.15 (m, 1H, H-6), 2.09 (s, 3H, CH3 Ac), 2.09 (s, 3H, CH3 Ac), 2.06 (s, 3H, 
CH3 Ac); 13C-APT NMR (CDCl3, 100 MHz, HSQC): δ 170.1, 169.5, 169.2 (C=O Ac), 86.1 (d, J = 197 
Hz, C-2), 85.3 (d, J = 25 Hz, C-1), 71.9 (C-5), 70.8 (d, J = 19 Hz, C-3), 66.3 (d, J = 7 Hz, C-4), 60.6 
(C-6), 20.4, 20.3 (CH3 Ac)). The crude bromide (~14.8 mmol) was dissolved in dry CHCl3 (150 mL), 
p-toluenethiol (2.76 g, 22.2 mmol) and TBAB (0.95 g, 2.96 mmol, dissolved in 20 mL H2O) were 
added and the resulting emulsion was cooled to 0 °C. Subsequently KOH (1.66 g, 29.6 mmol, 
dissolved in 20 mL H2O) was added during 10 minutes and the resulting emulsion was vigorously 
stirred at room temperature overnight. Next the organic layer was separated, washed with sat. aq. 
NaCl, dried over Na2SO4 and concentrated in vacuo. Purification using flash column chromatography 
(silica gel, 33% EtOAc in PE) yielded the title compound as a yellowish oil (Yield: 5.11 g, 12.3 mmol, 
83% over two steps). TLC: Rf 0.42 (PE/EtOAc, 2/1, v/v); [α]D20 +7.8º (c 1, DCM); IR (neat, cm-1): 
727, 908, 1030, 1217, 1744; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.40 (d, 2H, J = 8.1 
Hz, CHarom), 7.08 (d, 2H, J = 7.9 Hz, CHarom), 5.26 (dt, 1H, J = 9.1, 14.1 Hz, H-3), 4.86 (t, 1H, J = 9.8 
Hz, H-4), 4.60 (dd, 1H, J = 1.6, 9.7 Hz, H-1), 4.10-4.17 (m, 2.5H, H-2, H-6), 4.01 (t, 0.5H, J = 9.2 Hz, 
H-2), 3.68 (ddd, 1H, J = 3.1, 4.3, 10.1 Hz, H-5), 2.30 (s, 3H, CH3 STol), 2.01 (s, 3H CH3 Ac), 1.98 (s, 
3H, CH3 Ac), 1.96 (s, 3H, CH3 Ac); 13C-APT NMR (CDCl3, 100 MHz, HSQC): δ 170.2, 169.6, 169.3 
(C=O Ac), 138.9 (Cq Tol-CH3), 134.5, 129.5 (CHarom), 125.9 (Cq STol), 86.6 (d, J = 190 Hz, C-2), 83.8 
(d, J = 24 Hz, C-1), 75.4 (C-5), 73.6 (d, J = 20 Hz, C-3), 67.8 (d, J = 7 Hz, C-4), 61.7 (C-6), 21.0 (CH3 
STol), 20.5, 20.4, 20.3 (CH3 Ac); HRMS: [M+Na]+ calcd for C19H23FO7SNa 437.1041, found 
437.1039. 
 
Tolyl 2-deoxy-2-fluoro-1-thio-β-D-glucopyranoside (14). A solution of 
compound 13 (2.72 g, 6.56 mmol) in dry MeOH (50 mL) was treated with 
NaOMe (1.06 g, 19.7 mmol) for 30 minutes at room temperature under an argon atmosphere. The 
mixture was neutralized with Amberlite-H+, filtrated and concentrated in vacuo to yield the crude title 
compound as a white amorphous solid (Yield: quant.). TLC: Rf 0.46 (EtOAc); IR (neat, cm-1): 766, 
1009, 1047, 1364, 1614, 3277; 1H NMR (CDCl3/MeOH-d4, 400 MHz, HH-COSY, HSQC): δ 7.45 (d, 
2H, J = 8.0 Hz, CHarom), 7.14 (d, 2H, J = 8.0 Hz, CHarom), 4.64 (d, 1H, J = 9.6 Hz, H-1), 3.99 (dt, 1H, J 
= 9.2, 49.7 Hz, H-2), 3.87 (dd, 1H, J = 2.5, 12.2 Hz, H-6), 3.73 (dd, 1H, J = 4.7, 12.2 Hz, H-6), 3.63-
3.70 (m, 1H, H-3), 3.32-3.39 (m, 2H, H-4, H-5), 2.35 (s, 3H, CH3 STol); 13C-APT NMR 
(CDCl3/MeOH-d4, 100 MHz, HSQC): δ 138.4 (Cq Tol-CH3), 133.3, 129.5 (CHarom), 127.2 (Cq STol), 
89.5 (d, J = 186 Hz, C-2), 84.5 (d, J = 24 Hz, C-1), 79.9 (C-5), 75.9 (d, J = 18 Hz, C-3), 69.4 (d, J = 8 
Hz, C-4), 61.4 (C-6), 20.7 (CH3 STol); LC: Rt 5.53; linear gradient 10-90% B in 15 min; TLC-MS: 
m/z = 311.1 (M+Na+). 
 
Tolyl 2-deoxy-2-fluoro-1-thio-6-O-(p-toluenesulfonyl)-β-D-
glucopyranoside (15). Triol 14 (0.5 g, 1.74 mmol) was co-evaporated 
with dry dioxane (2x) and dissolved in dioxane (10 mL). The mixture was cooled to ~10 ºC, TEA 
(0.49 mL, 3.48 mmol) was added followed by the portion-wise addition of tosyl anhydride (0.62 g, 
1.92 mmol). The reaction was stirred overnight at RT and subsequently diluted with EtOAc. The 
organic layer was washed with sat. aq. NaCl (3x), dried over Na2SO4 and concentrated in vacuo. 
Purification using flash column chromatography (silica gel, 66% EtOAc in PE) furnished the title 
compound as a colored oil (Yield: 0.40 g, 0.90 mmol, 52%). TLC: Rf 0.71 (EtOAc); [α]D20 -2.8º (c 1, 
DCM); IR (neat, cm-1): 729, 1175, 1358, 2924, 3395; 1H NMR (CDCl3, 400 MHz, HH-COSY, 
HSQC): δ 7.77 (d, 2H, J = 8.3 Hz, CHarom), 7.32 (d, 2H, J = 8.1 Hz, CHarom), 7.29 (d, 2H, J = 8.2 Hz, 
CHarom), 7.03 (d, 2H, J = 8.1 Hz, CHarom), 4.63 (bs, 2H, 3-OH, 4-OH), 4.50 (d, 1H, J = 9.5 Hz, H-1), 
4.29 (d, 1H, J = 9.9 Hz, H-6), 4.21 (dd, 1H, J = 5.1, 11.0 Hz, H-6), 3.93 (dt, 1H, J = 9.1, 49.7 Hz, H-
2), 3.70 (dt, 1H, J = 8.7, 15.4 Hz, H-3), 3.35-3.50 (m, 2H, H-4, H-5), 2.38 (s, 3H, CH3 Ac), 2.29 (s, 
3H, CH3 Ac); 13C-APT NMR (CDCl3, 100 MHz, HSQC): δ 145.0 (Cq Ts-CH3), 138.4 (Cq Tol-CH3), 
133.5 (CHarom), 132.3 (Cq STs), 129.8, 129.7, 129.6, 127.9 (CHarom), 127.2 (Cq STol), 89.2 (d, J = 186 
Hz, C-2), 84.1 (d, J = 24 Hz, C-1), 76.8 (C-5), 76.0 (d, J = 18 Hz, C-3), 69.1 (d, J = 7 Hz, C-4), 68.6 
(C-6), 21.5, 21.0 (CH3 STol, Ts); HRMS: [M+Na]+ calcd for C20H23FO6S2Na 465.0812, found 
465.0811. 
 
Tolyl 6-azido-2,6-di-deoxy-2-fluoro-1-thio-β-D-glucopyranoside (17). 
A solution of compound 15 (1.59 g, 3.6 mmol) and sodium azide (0.7 g, 
10.8 mmol) in DMF (36 mL) was heated at 80 ºC overnight. The mixture was diluted with EtOAc, 
washed with sat. aq. NaHCO3 (2x) and H2O (2x), dried over Na2SO4 and concentrated in vacuo. The 
crude azide 16 was used in the next step without further purification. (TLC: Rf 0.37 (PE/EtOAc, 1/1, 
v/v); IR (neat, cm-1): 729, 1038, 1067, 1290, 2102, 3339; 1H NMR (CDCl3, 400 MHz, HH-COSY, 
HSQC): δ 7.46 (d, 2H, J = 8.1 Hz, CHarom), 7.13 (d, 2H, J = 8.0 Hz, CHarom), 4.54 (dd, 1H, J = 0.8, 9.6 
Hz, H-1), 4.40 (bs, 1H, 3-OH), 4.17 (bs, 1H, 4-OH), 3.95 (dt, 1H, J = 9.1, 49.6 Hz, H-2), 3.66 (dt, 1H, 
J = 7.1, 14.6 Hz, H-3), 3.54 (d, 1H, J = 12.1 Hz, H-6), 3.37-3.41 (m, 2H, H-4, H-5), 3.34 (d, 1H, J = 
13.3 Hz, H-6), 2.33 (s, 3H, CH3 STol); 13C-APT NMR (CDCl3, 100 MHz, HSQC): δ 139.1 (Cq Tol-
CH3), 134.7, 129.7 (CHarom), 126.0 (Cq STol), 89.2 (d, J = 185 Hz, C-2), 84.1 (d, J = 24 Hz, C-1), 78.2 
(C-5), 76.2 (d, J = 18 Hz, C-3), 69.7 (d, J = 7 Hz, C-4), 51.0 (C-6), 21.1 (CH3 STol)). Crude azido 
compound 16 (~3.6 mmol) was treated with pyridine/Ac2O (20 mL, 3/1, v/v) at RT overnight. The 
mixture was diluted with EtOAc, washed with sat. aq. NaCl (3x), dried over Na2SO4 and concentrated 
in vacuo. Purification using flash column chromatography (silica gel, 25% EtOAc in PE) yielded the 
title compound as an amorphous solid (Yield: 0.98 g, 2.47 mmol, 69% over two steps). TLC: Rf 0.85 
(PE/EtOAc, 1/1, v/v); [α]D20 +37.8º (c 1, DCM); IR (neat, cm-1): 729, 907, 1026, 1211, 1749, 2104; 1H 
NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 7.48 (d, 2H, J = 8.0 Hz, CHarom), 7.15 (d, 2H, J = 7.9 
Hz, CHarom), 5.31 (dt, 1H, J = 9.1, 14.1 Hz, H-3), 4.87 (t, 1H, J = 9.7 Hz, H-4), 4.66 (dd, 1H, J = 1.3, 
9.7 Hz, H-1), 4.10 (dt, 1H, J = 9.3, 49.0 Hz, H-2), 3.68 (ddd, 1H, J = 2.6, 5.9, 9.7 Hz, H-5), 3.37 (dd, 
1H, J = 2.5, 13.5 Hz, H-6), 3.26 (dd, 1H, J = 5.9, 13.5 Hz, H-6), 2.36 (s, 3H, CH3 STol), 2.03 (s, 3H, 
CH3 Ac), 2.00 (s, 3H, CH3 Ac); 13C-APT NMR (CDCl3, 100 MHz, HSQC): δ 169.6, 169.2 (C=O Ac), 
139.3 (Cq Tol-CH3), 135.1, 129.7 (CHarom), 125.1 (Cq STol), 86.4 (d, J = 190 Hz, C-2), 83.7 (d, J = 24 
Hz, C-1), 76.6 (C-5), 73.5 (d, J = 20 Hz, C-3), 68.7 (d, J = 7 Hz, C-4), 50.7 (C-6), 21.0 (CH3 Stol), 
20.4, 20.3 (CH3 Ac); HRMS: [M+Na]+ calcd for C17H23FNO5SNa 372.1275, found 372.1275. 
 
3,4-Di-O-acetyl-6-azido-2,6-di-deoxy-2-fluoro-α /β-D-glucopyranose 
(18). A solution of compound 17 (0.56 g, 1.41 mmol) in acetone/H2O (16 
mL, 3/1, v/v) was cooled to 0 °C followed by the addition of N-bromosuccinimide (0.75 g, 4.24 
mmol). The resulting solution was stirred at +4 °C overnight, after which analysis by TLC showed 
complete conversion of the starting material into two lower-running products. The addition of extra N-
bromosuccinimide (0.75 g, 4.24 mmol) and subsequent stirring at 0 °C for 3h resulted in full 
conversion into one spot as judged by TLC analysis. The reaction was quenched by the addition of sat. 
aq. Na2S2O3, diluted with EtOAc and washed with sat. aq. NaCl (3x). The organic layers were dried 
over Na2SO4 and concentrated in vacuo. Purification using flash column chromatography (silica gel, 
33% EtOAc in PE) yielded the title compound as a colorless oil (Yield: 0.36 g, 1.22 mmol, 86%, α : β 
= 4 : 1). TLC: Rf 0.54 (PE/EtOAc, 1/1, v/v); IR (neat, cm-1): 1024, 1213, 1747, 2104, 2924, 3443; 1H 
NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 5.56 (dt, 1H, J = 9.5, 12.0 Hz, H-3α), 5.48 (t, 1H, J = 
3.0 Hz, H-1α), 5.30 (dt, 0.25H, J = 9.7, 14.0 Hz, H-3β), 4.97 (t, 1H, J = 9.8 Hz, H-4α), 4.88-4.93 (m, 
0.25H, H-1β), 4.49 (ddd, 1H, J = 3.7, 9.6 49.5 Hz, H-2α), 4.34 (dd, 0.13H, J = 7.8, 9.1 Hz, H-2β), 
4.15-4.26 (m, 1.13H, H-2β, H-5α), 4.71 (ddd, 0.25H, J = 3.7, 5.5, 13.6 Hz, H-5β), 3.37 (dd, 1H, J = 
2.8, 13.4 Hz, H-6α), 3.33-3.35 (m, 0.5H, H-6β), 3.27 (dd, 1H, J = 5.8, 13.4 Hz, H-6α), 2.07 (s, 0.75H, 
CH3 Ac-β), 2.06 (s, 3H, CH3 Ac-α), 2.03 (s, 3H, CH3 Ac-α), 2.03 (s, 0.75H, CH3 Ac-β); 13C-APT 
NMR (CDCl3, 100 MHz, HSQC): δ 170.5, 170.0 (C=O Ac), 94.4 (d, J = 23 Hz, C-1β), 90.3 (d, J = 
189 Hz, C-2β), 89.9 (d, J = 26 Hz, C-1α), 87.6 (d, J = 192 Hz, C-2α), 72.9 (C-5β), 72.6 (d, J = 20 Hz, 
C-3β), 70.3 (d, J = 19 Hz, C-3α), 69.2 (d, J = 7 Hz, C-4β), 69.1 (d, J = 7 Hz, C-4α), 68.2 (C-5α), 50.7 
(C-6), 20.7 (CH3 Ac-α), 20.6 (CH3 Ac-β), 20.5 (CH3 Ac-α), 20.5 (CH3 Ac-β); HRMS: [M(amine)+H]+ 
calcd for C10H17FNO6 266.10344, found 266.10365. 
 
6-Azido-2,6-di-deoxy-2-fluoro-β-D-glucopyranosyl fluoride (6). Compound 
18 (60 mg, 0.21 mmol) was dissolved in dry DCM (4 mL) under an argon 
atmosphere. The solution was cooled to -45 °C and treated with DAST (63 µL, 0.52 mmol). The 
mixture was stirred at -45 °C for 1.5 h and quenched with MeOH (0.15 mL). After warming to RT the 
mixture was diluted with EtOAc, washed with sat. aq. NaCl, dried over Na2SO4 and concentrated in 
vacuo to yield the crude product as an anomeric mixture (α : β = 1 : 4). The anomers were partly 
separated using flash column chromatography to yield the beta fluoride as a colorless oil (Yield: 39 
mg, 0.13 mmol, 64%). TLC: Rf 0.50 (PE/EtOAc, 2/1, v/v); [α]D20 +113.5º (c 1, DCM); IR (neat, cm-1): 
1028, 1099, 1207, 1749, 2104; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 5.48 (ddd, 1H, J = 
3.8, 6.2, 52.0 Hz, H-1), 5.34 (dt, 1H, J = 8.3, 15.4 Hz, H-3), 5.10 (t, 1H, J = 9.3 Hz, H-4), 4.50 (dddd, 
1H, J = 6.2, 8.0, 11.1, 49.9 Hz, H-2), 3.87 (ddd, 1H, J = 3.3, 5.8, 9.3 Hz, H-5), 3.46 (dd, 1H, J = 3.2, 
13.5 Hz, H-6), 3.41 (dd, 1H, J = 5.8, 13.5 Hz, H-6), 2.10 (s, 3H, CH3 Ac), 2.06 (s, 3H, CH3 Ac); 13C-
APT NMR (CDCl3, 100 MHz, HSQC): δ 169.7, 169.3 (C=O Ac), 105.7 (dd, J = 27, 218 Hz, C-1), 
88.7 (dd, J = 28, 189 Hz, C-2), 73.0 (d, J = 4 Hz, C-5), 71.3 (dd, J = 9, 21 Hz, C-3), 68.0 (d, J = 7 Hz, 
C-4), 50.7 (C-6), 20.4, 20.4 (CH3 Ac); HRMS: [M+Na]+ calcd for C10H13F2N3O5Na 316.07155, found 
316.07167. The peracetylated fluoride (85 mg, 0.29 mmol) was dissolved in MeOH (3 mL) and treated 
with cat. NaOMe (~ 1 mg) for 75 mins at RT. The mixture was neutralized with Amberlite-H+, 
filtrated and concentrated in vacuo. Purification using flash column chromatography (silica gel, 66% 
EtOAc in PE) yielded compound 6 as a colorless oil (Yield: 62 mg, 0.29 mmol, 100%). TLC: Rf 0.13 
(PE/EtOAc, 2/1, v/v); [α]D20 +54.8º (c 1, MeOH); IR (neat, cm-1): 1005, 1074, 1099, 2106, 3352; 1H 
NMR (MeOH-d4, 400 MHz, HH-COSY, HSQC): δ 5.39 (ddd, 1H, J = 3.5, 6.9, 53.2 Hz, H-1), 4.18 
(dddd, 1H, J = 7.0, 8.9, 13.4, 51.6 Hz, H-2), 3.59-3.72 (m, 3H, H-3, H-5, H-6), 3.94 (dd, 1H, J = 5.1, 
12.6 Hz, H-6), 3.43 (t, 1H, J = 9.3 Hz, H-4); 13C-APT NMR (MeOH-d4, 100 MHz, HSQC): δ 108.0 
(dd, J = 26, 213 Hz, C-1), 93.5 (dd, J = 24, 185 Hz, C-2), 76.7 (d, J = 5 Hz, C-5), 75.1 (dd, J = 10, 18 
Hz, C-3), 71.1 (d, J = 8 Hz, C-4), 52.2 (C-6); LC: Rt 7.26; linear gradient 10-90% B in 15 min; TLC-
MS: m/z = 441.3 (2M+Na+). 
 
2,4-Di-nitrophenyl 6-azido-2,6-di-deoxy-2-fluoro-β-D-
glucopyranoside (9). Compound 18 (58 mg, 0.20 mmol) was 
dissolved in dry DMF (3 mL). The mixture was cooled to 0 
ºC and 2,4-dinitrofluorobenzene (56 mL, 0.44 mmol) and DABCO (91 mg, 0.81 mmol) were added. 
After 5h the mixture was diluted with EtOAc, washed with sat. aq. NaCl (3x), dried over Na2SO4 and 
concentrated in vacuo. Purification using flash column chromatography (silica gel, 66% EtOAc in PE) 
yielded the β-fused compound as a yellowish oil (Yield: 33 mg, 72 µmol, 36%). TLC: Rf 0.17 
(PE/EtOAc, 2/1, v/v); [α]D20 -88.9º (c 1, DCM); IR (neat, cm-1): 1034, 1067, 1229, 1348, 1537, 1609, 
1753, 2104; 1H NMR (CDCl3, 400 MHz, HH-COSY, HSQC): δ 8.77 (d, 1H, J = 2.7 Hz, CHarom), 8.48 
(dd, 1H, J = 2.8, 9.2 Hz, CHarom), 7.45 (d, 1H, J = 9.2 Hz, CHarom), 5.40-5.50 (m, 2H, H-1, H-3), 5.05 
(t, 1H, J = 9.5 Hz, H-4), 4.72 (ddd, 1H, J = 7.2, 8.6, 49.8 Hz, H-2), 3.92 (ddd, 1H, J = 2.7, 7.5, 10.0 
Hz, H-5), 3.47 (dd, 1H, J = 7.5, 13.5 Hz, H-6), 3.38 (dd, 1H, J = 2.7, 13.5 Hz, H-6), 2.13 (s, 3H, CH3 
Ac), 2.08 (s, 3H, CH3 Ac); 13C-APT NMR (CDCl3, 100 MHz, HSQC): δ 169.8, 169.4 (C=O Ac), 
153.2, 142.3, 140.1 (Cq), 128.9, 121.7, 117.8 (CHarom), 98.2  (d, J = 25 Hz, C-1), 88.4 (d, J = 192 Hz, 
C-2), 74.1 (C-5), 71.6 (d, J = 21 Hz, C-3), 68.5 (d, J = 7 Hz, C-4), 51.0 (C-6), 20.5, 20.5 (CH3 Ac); 
TLC-MS: m/z = 480.1 (M+Na+). A solution of peracetylated compound (33 mg, 72 µmol) in dry 
MeOH (1 mL) was treated with acetyl chloride (~4 drops) at RT until TLC analysis indicated 
complete conversion into one product (5 days). The mixture was quenched with TEA till pH ~ neutral, 
diluted with EtOAc and concentrated in vacuo. Purification using flash column chromatography (silica 
gel, 75% EtOAc in PE) furnished the title compound as a colorless oil (Yield: 24 mg, 64.2 µmol, 
89%). TLC: Rf 0.25 (PE/EtOAc, 1/2, v/v); [α]D20 -148.0º (c 0.5, MeOH); IR (neat, cm-1): 1069, 1281, 
1348, 1535, 1609, 2104, 3395; 1H NMR (MeOH-d4, 400 MHz, HH-COSY, HSQC): δ 8.74 (d, 1H, J = 
2.8 Hz, CHarom), 8.50 (dd, 1H, J = 2.8, 9.3 Hz, CHarom), 7.66 (d, 1H, J = 9.3 Hz, CHarom), 5.64 (dd, 1H, J 
= 3.2, 7.5 Hz, H-1), 4.35 (ddd, 1H, J = 7.6, 8.9, 51.3 Hz, H-2), 3.71-3.82 (m, 2H, H-3, H-5), 3.60 (dd, 
1H, J = 2.3, 13.4 Hz, H-6), 3.49 (dd, 1H, J = 7.0, 13.4 Hz, H-6), 3.42 (t, 1H, J = 9.4 Hz, H-4); 13C-
APT NMR (MeOH-d4, 100 MHz, HSQC): δ 154.8, 143.2, 141.2 (Cq), 129.8, 122.2, 118.9 (CHarom), 
99.2 (d, J = 25 Hz, C-1), 92.8 (d, J = 187 Hz, C-2), 77.5 (C-5), 75.7 (d, J = 17 Hz, C-3), 71.5 (d, J = 8 
Hz, C-4), 52.5 (C-6); TLC-MS: m/z = 764.6 (2M+NH4+). 
MW448 (4). Compound 6 (5.8 mg, 27.7 µmol) 
and Bodipy-alkyne 10 (9.98 mg, 30.4 µmol) 
were together dissolved in DMF (0.5 mL), 
followed by the addition of sodium ascorbate (4.1 µL, 1 M) and copper(II)sulfate (2.7 µL, 1 M). The 
solution was stirred at 45 °C overnight and extra sodium ascorbate and copper(II)sulfate were added. 
After 2 days, the mixture was concentrated in vacuo and purified using flash column chromatography 
(silica gel, 5% MeOH in DCM) to yield the title compound as a bright orange solid (Yield: 8.4 mg, 
15.6 µmol, 56%). TLC: Rf 0.23 (DCM/MeOH, 9/1, v/v); IR (neat, cm-1): 986, 1202, 1510, 1551, 2926, 
3333; 1H NMR (CDCl3/MeOH-d4, 600 MHz, HH-COSY, HSQC): δ 6.06 (s, 2H, CH-pyrole), 5.26 
(ddd, 1H, J = 3.6, 6.2, 52.6 Hz, H-1), 4.77 (d, 1H, J = 14.1 Hz, H-6), 4.65 (dd, 1H, J = 4.2, 13.9 Hz, 
H-6), 4.15 (dddd, 1H, J = 7.9, 8.1, 12.9, 51.6 Hz, H-2), 3.67-3.78 (m, 2H, H-3, H-5), 3.16 (t, 1H, J = 
9.1 Hz, H-4), 3.01 (bs, 2H, CH2), 2.80 (bs, 2H, CH2), 2.50 (s, 6H, CH3), 2.40 (s, 6H, CH3), 1.93 (bs, 
2H, CH2), 1.71 (bs, 2H, CH2); 13C-APT NMR (CDCl3, 125 MHz, HSQC): δ 153.6, 145.8, 140.3, 131.1 
(Cq), 121.5 (CHarom), 106.2 (dd, J = 22, 180 Hz, C-1), 91.4 (dd, J = 20, 155 Hz, C-2), 74.1 (d, J = 4 Hz, 
C-5), 73.3 (dd, J = 8, 15 Hz, C-3), 69.4 (d, J = 7 Hz, C-4), 50.7 (C-6), 31.1, 29.4, 29.2, 27.8, 25.0 
(CH2), 16.0, 14.0 (CH3); LC/MS: Rt 8.23; linear gradient 10-90% B in 15 min; ESI-MS: m/z = 537.7 
(M+H+); HRMS: [M+H]+ calcd for C25H33BF4N5O3 538.26071, found 538.26041. 
 
MW454 (7). Compound 9 (9.2 
mg, 24.6 µmol) and Bodipy-
alkyne 10 (10.2 mg, 31.1 µmol) 
were together dissolved in DMF 
(0.5 mL), followed by the addition 
of sodium ascorbate (3.7 µL, 1 M) 
and copper(II)sulfate (2.5 µL, 1 M). The solution was stirred at 45 °C overnight and extra sodium 
ascorbate and copper(II)sulfate were added. After 2 days, the mixture was concentrated in vacuo and 
purified using flash column chromatography (silica gel, 5% MeOH in DCM) to yield the title 
compound as an orange solid (Yield: 3.6 mg, 5.1 µmol, 21%). TLC: Rf 0.18 (CH2Cl2/MeOH, 19/1, 
v/v); IR (neat, cm-1): 1070, 1200, 1348, 1541, 1609, 2102, 3350; 1H NMR (CDCl3/MeOH-d4, 600 
MHz, HH-COSY, HSQC): δ 8.69 (d, 1H, J = 2.6 Hz, CHarom), 8.27 (dd, 1H, J = 2.6, 9.1 Hz, CHarom), 
7.33 (s, 1H, CH-triazole), 6.96 (d, 1H, J = 9.2 Hz, CHarom),   6.05 (s, 1H, CH-pyrole), 5.21 (dd, 1H, J = 
2.9, 7.5 Hz, H-1), 4.83 (dd, 1H, J = 1.3, 14.3 Hz, H-6), 4.43-4.50 (m, 1.5 H, H-2, H-6), 4.37 (t, 0.5H, J 
= 8.2 Hz, H-2), 3.99 (t, 1H, J = 7.8 Hz, H-5), 3.81 (dt, 1H, J = 8.9, 15.8 Hz, H-3), 3.33 (t, 1H, J = 9.4 
Hz, H-4), 2.93-3.02 (m, 2H, CH2), 2.74-2.79 (m, 2H, CH2), 2.49 (s, 6H, CH3), 2.37 (bs, 6H, CH3), 
1.81-1.94 (m, 2H, CH2), 1.58-1.70 (m, 2H, CH2); 13C-APT NMR (CDCl3/MeOH-d4, 125 MHz, 
HSQC): δ 153.4, 145.7, 141.9, 131.2 (Cq), 128.6, 121.3, 117.9 (CHarom), 98.6 (d, J = 21 Hz, C-1), 90.7 
(d, J = 157 Hz, C-2), 74.7 (C-5), 74.4 (d, J = 15 Hz, C-3), 70.2 (d, J = 7 Hz, C-4), 50.6 (C-6), 31.2, 
29.4, 27.9, 25.1 (CH2), 16.2, 14.2 (CH3); LC/MS: Rt 8.94; linear gradient 10-90% B in 15 min; ESI-
MS: m/z = 701.9 (M+H+); HRMS: [M+H]+ calcd for C31H36BF3N7O8 702.26650, found 702.26640. 
 
MW461 (5). Compound 6 (7.6 
mg, 36.3 µmol) and Bodipy-
alkyne 10 (24.4 mg, 50.3 µmol) 
were together dissolved in DMF 
(0.5 mL), followed by the 
addition of sodium ascorbate (5.4 µL, 1 M and copper(II)sulfate (3.6 µL, 1 M). The solution was stirred 
at 45 °C overnight and extra sodium ascorbate and copper(II)sulfate were added. Then the mixture was 
concentrated in vacuo and purified using HPLC to yield the title compound as a dark blue solid (Yield: 
9.2 mg, 13.2 µmol, 36%). IR (neat, cm-1): 1067, 1142, 1468, 1566, 2853, 2920, 3366; 1H NMR 
(CDCl3/MeOH-d4, 600 MHz, HH-COSY, HSQC): δ 7.83 (d, 4H, J = 8.8 Hz, CHarom), 7.47 (s, 1H, CH-
pyrole), 7.27 (d, 2H, J = 4.3 Hz, CH-pyrole), 6.94 (d, 4H, J = 8.8 Hz, CHarom), 6.61 (d, 2H, J = 4.2 Hz, 
CH-pyrole), 5.27 (ddd, 1H, J = 3.8, 6.5, 52.6 Hz, H-1), 4.75 (dd, 1H, J = 2.3, 14.6 Hz, H-6), 4.61 (dd, 
1H, J = 5.9, 14.6 Hz, H-6), 4.16 (dddd, 1H, J = 7.0, 8.5, 12.8, 51.1 Hz, H-2), 3.85 (s, 6H, OMe), 3.66-
3.77 (m, 2H, H-3, H-5), 3.17 (t, 1H, J = 9.4 Hz, H-4), 2.99 (app t, 2H, J = 7.1 Hz, CH2), 2.79 (t, 2H, J 
= 6.5 Hz, CH2), 1.88 (bs, 4H, CH2); 13C-APT NMR (CDCl3/MeOH-d4, 125 MHz, HSQC): δ 160.4, 
157.5, 147.4, 144.6, 136.1 (Cq), 130.9, 126.7 (CHarom), 125.1 (Cq), 123.1, 119.9, 113.6 (CHarom), 106.4 
(dd, J = 23, 180 Hz, C-1), 91.4 (dd, J = 21, 154 Hz, C-2), 74.3 (d, J = 4 Hz, C-5), 73.5 (dd, J = 8, 15 
Hz, C-3), 69.3 (d, J = 7 Hz, C-4), 55.2 (OMe), 50.1 (C-6), 33.0, 30.3, 29.6, 25.0 (CH2); LC/MS: Rt 
9.30; linear gradient 10-90% B in 15 min; ESI-MS: m/z = 693.9 (M+H+). HRMS: [M+H]+ calcd for 




(13.5 mg, 36.0 
µmol) and 
Bodipy-alkyne 10 
(35.0 mg, 72 
µmol) were together dissolved in DMF (1 mL), followed by the addition of sodium ascorbate (5.4 µL, 
1 M) and copper(II)sulfate (3.6 µL, 1 M). The solution was stirred at 45 °C overnight and extra sodium 
ascorbate and copper(II)sulfate were added. After 2 days, the mixture was concentrated in vacuo and 
purified using HPLC to yield the title compound as a blue solid (Yield: 10 mg, 11.6 µmol, 32%). IR 
(neat, cm-1): 1069, 1142, 1466, 1572, 1684, 2853, 2926, 3395; 1H NMR (CDCl3/MeOH-d4, 600 MHz, 
HH-COSY, HSQC): δ 8.69 (d, 1H, J = 2.7 Hz, CHarom), 8.30 (dd, 1H, J = 2.8, 9.2 Hz, CHarom), 7.81 (d, 
4H, J = 8.8 Hz, CHarom), 7.30 (s, 2H, CH-pyrole), 7.25 (d, 2H, J = 4.3 Hz, CH-pyrole), 7.00 (d, 1H, J = 
9.3 Hz, CHarom), 6.94 (d, 4H, J = 8.9 Hz, CHarom), 6.60 (d, 2H, J = 4.3 Hz, CH-pyrole), 5.26 (dd, 1H, J 
= 3.0, 7.6 Hz, H-1), 4.80 (dd, 1H, J = 2.3, 14.5 Hz, H-6), 4.46 (app dd, 1H, J = 7.9, 14.6 Hz, H-6), 
4.39 (ddd, 1H, J = 7.8, 8.7, 51.0 Hz, H-2), 3.99-4.03 (m, 1H, H-5), 3.77-3.86 (m, 1H, H-3), 3.85 (s, 
6H, OMe), 3.30 (t, 1H, J = 9.4 Hz, H-4), 2.97 (t, 2H, J = 7.2 Hz, CH2), 2.67-2.80 (m, 2H, CH2), 1.80-
1.90 (m, 4H, CH2); 13C-APT NMR (CDCl3/MeOH-d4, 125 MHz, HSQC): δ 160.4, 157.5, 153.4, 144.5, 
141.8, 139.9, 136.0 (Cq),130.8, 128.6, 126.7 (CHarom), 125.0 (Cq), 123.0, 121.3, 119.9, 117.8, 113.6 
(CHarom), 98.4 (d, J = 21 Hz, C-1), 90.7 (d, J = 157 Hz, C-2), 74.6 (C-5), 74.2 (d, J = 15 Hz, C-3), 70.2 
(d, J = 7 Hz, C-4), 55.2 (OMe), 50.5 (C-6), 32.9, 31.8, 29.2, 25.0 (CH2); LC/MS: Rt 9.90; linear 
gradient 10-90% B in 15 min; ESI-MS: m/z = 857.9 (M+H+). HRMS: [M+H]+ calcd for 
C41H40BF3N7O10 858.28834, found 858.28884. 
Two-step labeling: Staudinger ligation versus copper catalyzed click-reaction 
Recombinant purified glucocerebrosidase (5 µL, 1 mg/mL) was added to PBS (5 µL, pH 7.4) 
containing BSA (5 mg/mL) and KY170 3 (200 µM). After incubating on ice for 30 min, 5 µL of the 
solution was added to 45 µL McIlvain buffer (50 mM citric acid, 100 mM Na2HPO4, pH 5.2 containing 
0.2% sodium taurocholate, 0.1% Triton X-100) and the resulting mixture was incubated at 37°C for 30 
minutes. The inhibited enzyme was aliquoted over eppendorf tubes (5 µL per eppendorf). Staudinger 
ligation: To remove excess probe, the proteins were precipitated using chloroform/methanol 
precipitation.5 The protein pellet was redissolved in McIlvain buffer (10 µL) containing 6M Urea and 6 
mM beta-mercaptoethanol. To this was added 1 µL of Staudinger-biotin phosphane 20 (4 mM stock 
solution in DMF stored under inert atmosphere at -80°C) and the resulting mixture was incubated at 
37°C for 2 hours. The reaction was quenched by adding Laemli sample buffer (4×) and boiling for 5 
min. 
Click reaction: To remove excess probe, the proteins were precipitated using chloroform/methanol 
precipitation. The protein pellet was redissolved in 100 µL NaOAc buffer (50 mM, pH 6.0) containing 
SDS (1%). CuSO4 (1 µL, 0.1 M), dithiothreitol (0.5 µL, 0.1 M) and either biotin-alkyne 21 or 
BODIPY-alkyne 10 (1 µL, 200 µM) were added and the reaction was incubated 1h at room 
temperature. The proteins were precipitated by the addition of ice-cold acetone (1 mL) and incubating 
at -20°C for 1h before being pelletized by centrifugation at 16,000× g at 4°C for 20 min. The 
supernatant was removed and the protein pellet was redissolved in Laemli sample buffer (2×).  
The proteins were denatured by boiling for 5 min before being loaded on a 7.5% SDS-PAGE gel. 
Proteins modified with biotin as a reporter group were transferred to a PVDF-membrane. The 
membranes were blocked with 0.5% bovine serum albumin in TBS-TWEEN (0.1% TWEEN-20) for 
30 min and incubated with Streptavidine-HRP (Amersham Bioscience 1:5000) for 30 min at ambient 
temperature. The membranes were briefly washed with TBS containing 0.1% TWEEN-20 and TBS 
followed by visualisation of the biotinylated proteins with an ECL+ Kit (Amersham Bioscience). 
Optimization of the click reaction 
Optimization of the time of labeling: To GBA-1 (100 ng) pre-treated with KY170 3 (1 µL, 100 µM) at 
37°C for 30 min was added NaOAc buffer (80 µL, 50 mM pH 6.0, 0.1% SDS). A fresh mixture of 
TBTA (10 µL, 2 mM in DMF), CuSO4 (1 µL, 0.1 M in H2O), DTT (0.5 µL, 0.1 M in H2O) and 
BODIPY-alkyne 10 (0.5 µL, 2 mM in MeCN) was prepared, added to the enzyme solution and the 
resulting mixture was incubated for respectively 1, 2, 4 or 16 hours at room temperature. The proteins 
were precipitated by the addition of ice-cold acetone (1 mL) followed by incubating at -20°C for 20 
min and centrifugation (16,000× g, 15 min) at 4°C. The proteins were redissolved in 2× sample buffer 
(15 µL) and loaded on a 7.5% SDS-PAGE gel. The fluorescence was measured in the wet gel slabs 
using the CY2 settings (λex 488, λem 520) on a Typhoon Variable Mode Imager (Amersham 
Biosciences). 
Optimization of the reductor: To GBA-1 (100 ng) pre-treated with KY170 3 (1 µL, 100 µM) at 37°C 
for 30 min was added NaOAc buffer (80 µL, 50 mM pH 6.0, 0.1% SDS). To a fresh mixture of TBTA 
(10 µL, 2 mM in DMF), copper (II) sulfate (1 µL, 0.1 M in H2O) and BODIPY-alkyne 10 (0.5 µL, 2 
mM in MeCN) was added respectively DTT (0.5 µL, 0.1 M in H2O), TCEP (0.5 µL, 0.2 M in H2O) or 
sodium ascorbate (0.5 µL, 0.2 M in H2O) before being added to the enzyme solution. The resulting 
mixture was incubated for 16 hours at room temperature. The reaction was quenched and the labeled 
proteins were visualized as described above. 
Optimization of amount of copper (II) sulfate: To GBA-1 (100 ng) pre-treated with KY170 3 (1 µL, 
100 µM) at 37°C for 30 min was added NaOAc buffer (80 µL, 50 mM pH 6.0, 0.1% SDS). A fresh 
mixture of TBTA (10 µL, 2 mM in DMF), copper (II) sulfate (1 µL, 100× stock in H2O, final 
concentrations: 50, 100, 500 and 1000 µM), DTT (0.5 µL, 100× stock in H2O, 0.5 equivalents 
compared to copper (II) sulfate) and BODIPY-alkyne 10 (0.5 µL, 2 mM in MeCN) was prepared, 
added to the enzyme solution and the resulting mixture was incubated for 16 hours at room 
temperature. The reaction was quenched and the labeled proteins were visualized as described above. 
Optimization of the amount of SDS: To GBA-1 (100 ng) pre-treated with KY170 3 (1 µL, 100 µM) at 
37°C for 30 min was added NaOAc buffer (80 µL, 50 mM pH 6.0) containing SDS (respectively 
0.05%, 0.1%, 0.5% or 1% (w/v)). A fresh mixture of TBTA (10 µL, 2 mM in DMF), copper (II) sulfate 
(1 µL, 0.1 M in H2O), DTT (0.5 µL, 0.1 M in H2O) and BODIPY-alkyne 10 (0.5 µL, 2 mM in MeCN) 
was prepared, added to the enzyme solution and the resulting mixture was incubated for 16 hours at 
room temperature. The reaction was quenched and the labeled proteins were visualized as described 
above. 
Optimization of the amount of BODIPY-alkyne 10: To GBA-1 (100 ng) pre-treated with KY170 3 (1 
µL, 100 µM) at 37°C for 30 min was added NaOAc buffer (80 µL, 50 mM pH 6.0, 0.1% SDS). A fresh 
mixture of TBTA (10 µL, 2 mM in DMF), copper (II) sulfate (1 µL, 0.1 M in H2O), DTT (0.5 µL, 0.1 
M in H2O) and BODIPY-alkyne 10 (0.5 µL, 100× stock in MeCN, final concentrations: 0.1, 0.5, 1, 5 
and 10 µM) was prepared, added to the enzyme solution and the resulting mixture was incubated for 
16 hours at room temperature. The reaction was quenched and the labeled proteins were visualized as 
described above. 
Competition experiments 
Protocol for irreversible inhibitors: 9 µL of GBA-1 (20 ng) in reaction buffer was preincubated with 
CBE (1 µL, 2 mM final concentration) at 37°C for 30 min followed by incubation with the probe (3: 
10 µM for 30 min, 4: 400 µM for 6 h and 5: 100 µM for 6 h). The reaction was quenched either by the 
addition of 4× SDS-PAGE sample buffer (5 µL) (4 and 5) or by the addition of the click buffer (3). 
The samples were treated and analyzed by SDS-PAGE as described above for the labeling 
experiments.  
Protocol for reversible inhibitors: 9 µL of GBA-1 (20 ng) in reaction buffer was incubated with AMP-
DNM (1 µL, 2 mM final concentration) in combination with 1 µL of the probe (final concentrations: 3: 
10 µM for 30 min, 4: 400 µM for 6 h and 5: 100 µM for 6 h). After quenching of the reaction, the 
samples were handled as described above. 
Protocol for heat-inactivation: 1 µL SDS (10%) was added to 9 µL of GBA-1 (20 ng) in reaction 
buffer. The enzyme was heated at 100°C for 5 min, cooled to rt after which 1 µL of the probe (final 
concentrations: 3: 10 µM for 30 min, 4: 400 µM for 6 h and 5: 400 µM for 6 h) was added. After 
incubating the sample at 37°C for 30 min, the samples were handled as described above. 
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